Trial Profile
A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Becaplermin (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Ethicon
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 20 May 2010 New trial record